Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lanreotid, ATC H01CB03 für die Zeit 01.04.2026 - 31.03.2027 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a (8) SGB V allows health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance companies. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, for the above-mentioned active substance Lanreotid, ATC H01CB03, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until new pharmaceutical discount contracts come into force. A discount contract under the approval model for the above-mentioned active substance comes into force for the first time on 01.04.2026 and expires on 31.03.2027 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.